article thumbnail

3 Reasons Tilray Brands Investors Shouldn't Assume U.S. Marijuana Legalization Would Fix the Stock's Problems

The Motley Fool

legalizes marijuana. Here are three reasons marijuana legalization in the U.S. Tilray may aggressively pursue mergers and acquisitions Tilray hasn't been shy when it comes to acquisitions. If it were to pursue more risky acquisitions in the U.S., won't solve Tilray's problems.

Legal 246
article thumbnail

Rinkelberg Capital acquires Jus-Rol from Cérélia following CMA ruling

Private Equity Insights

The CMA originally ordered Crlia to divest Jus-Rol after ruling in 2023 that the acquisition reduced competition in the UKs 100m ready-to-bake dough category. The legal battle cost the company nearly 6m. The CMA confirmed the closure of its merger investigation following the sale. Can`t stop reading?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top private equity news of the week

Private Equity Insights

The regulator, which launched the probe in December over competition concerns, confirmed on Wednesday that it will not escalate the merger to a further in-depth investigation. Several buyout firms have unknowingly backed data centres used by ByteDance, some of which may have provided a legal workaround for acquiring high-end Nvidia chips.

article thumbnail

Judge Approves Microsoft-Activision Merger

The Motley Fool

The biggest merger in tech industry history just got the green light. On Tuesday, a federal judge in California denied the Federal Trade Commission's request for a preliminary injunction seeking to block Microsoft's monster $69 billion deal to acquire games-maker Activision Blizzard -- in effect, giving the merger the go-ahead.

article thumbnail

3 Top Growth Stocks to Buy in September

The Motley Fool

Despite an unfavorable macroeconomic situation and cannabis' legal ambiguity in the U.S. cannabis market, and a growing international presence, Curaleaf stock could be poised for a healthy rebound after its stock lost over 40% of its value over the prior 12 months and as legalization momentum builds.

article thumbnail

Pharma Giants Combine Forces to Fight New M&A Rules

The Motley Fool

With a looming overhaul of US merger-and-acquisition law set to reshape the economics of the M&A-heavy pharmaceutical industry, 31 of its biggest players -- including Merck, Amgen, Abbvie, and Gilead -- formed an alliance to fight the reforms. billion merger with Horizon Therapeutics. Meet the anti-antitrust coalition.

article thumbnail

There's a Major Deal Brewing Between a Top Cannabis Producer and a Leading Beer Maker

The Motley Fool

But due to the federal ban on pot, many companies shy away from trying to collaborate or engage in mergers and acquisitions with marijuana producers. While there are Canadian-based cannabis stocks that trade on the Nasdaq, it's because pot isn't illegal in Canada (it was legalized in 2018). But for U.S.-based